Definitive Healthcare (NASDAQ:DH) Given New $1.00 Price Target at Barclays

Definitive Healthcare (NASDAQ:DH) had its target price decreased by Barclays from $2.75 to $1.00 in a research report sent to investors on Monday morning,Benzinga reports. Barclays currently has an underweight rating on the stock.

Several other brokerages have also commented on DH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definitive Healthcare in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Canaccord Genuity Group lowered their price target on shares of Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating on the stock in a report on Friday, February 27th. Morgan Stanley reissued an “underperform” rating and set a $3.50 price objective on shares of Definitive Healthcare in a report on Thursday, December 18th. Finally, Stephens decreased their target price on Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $3.27.

Definitive Healthcare Trading Up 10.5%

NASDAQ DH opened at $1.16 on Monday. The business’s fifty day moving average is $1.58 and its 200-day moving average is $2.45. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.64 and a quick ratio of 1.64. The stock has a market capitalization of $121.19 million, a price-to-earnings ratio of -0.93 and a beta of 1.66. Definitive Healthcare has a one year low of $0.97 and a one year high of $4.70.

Institutional Trading of Definitive Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new stake in shares of Definitive Healthcare during the 2nd quarter valued at approximately $32,000. State of Alaska Department of Revenue grew its stake in Definitive Healthcare by 109.3% in the 4th quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock valued at $32,000 after buying an additional 5,970 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in Definitive Healthcare during the 4th quarter valued at $35,000. Ariadne Wealth Management LP bought a new stake in Definitive Healthcare during the 3rd quarter valued at $54,000. Finally, Bayesian Capital Management LP purchased a new stake in shares of Definitive Healthcare during the second quarter worth $55,000. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.